Estrella Immunopharma, Inc. (ESLA)
Estrella Immunopharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in EmeryVille, CA, US. The stock last traded at $0.74, up 4.60% on the session, giving a market capitalisation of $31.5M. On trailing twelve-month figures it carries a trailing P/E of -2.13, a net margin of 0.0%. Its beta of 0.89 implies it has historically moved less than the broad market.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Estrella Immunopharma, Inc. is most often compared with the following Healthcare names: